Manufacturing Efficiency, Manufacturing Cost Reduction and Quality Control
First written in FY2016. 12 of 37 entries say "Advanced", first in FY2018. Latest entry: FY2026.
Fuso Pharmaceutical Industries moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).
6 other companies' latest entry also says "Other".
- FY2026Updated: full-year profit decline due to higher raw-material and labor costs and increased R&D expensesAnnual report
「On the earnings front, operating profit was ¥2,639 million, down ¥1,491 million (36.1%) from the same period of the previous year, due mainly to a higher-than-expected increase in the cost of sales ratio resulting from higher raw material and personnel costs, as well as increased research and development expenses accompanying progress in R&D activities related to DMX-200. Ordinary profit was ¥2,349 million, down ¥1,431 million (37.9%), while net profit for the period was ¥2,011 million, compared with a net loss of ¥3,288 million for the same period of the previous year.」
The full-year operating profit declined 36.1% year on year and ordinary profit declined 37.9% due to a higher cost of sales ratio resulting from raw material and personnel costs and increased research and development expenses for DMX-200. - FY2026-H1Updated for the decline in profit due to higher raw material and personnel costs and increased research and development expensesAnnual report
「On the earnings front, operating profit was ¥1,247 million, down ¥1,186 million (48.8%) from the same period of the previous year, due mainly to a higher-than-expected increase in the cost of sales ratio resulting from higher raw material and personnel costs, as well as increased research and development expenses accompanying progress in R&D activities related to DMX-200. Ordinary profit was ¥1,131 million, down ¥1,012 million (47.2%), while interim net profit was ¥831 million, down ¥703 million (45.8%).」
Operating profit, ordinary profit and interim net profit declined year on year due to a higher-than-expected increase in the cost of sales ratio resulting from higher raw material and personnel costs, as well as increased research and development expenses for DMX-200. - FY2025AdvancedAnnual report
「On the earnings front, although raw material and logistics-related costs and other expenses continued to rise, the unprofitability of the infusion business as a whole eased due to increased production and the effects of exceptional recalculation of prices for unprofitable products. As a result, the cost of sales ratio improved slightly, operating profit increased ¥2,167 million (110.3%) to ¥4,131 million from the same period of the previous year, and ordinary profit increased ¥1,912 million (102.4%) to ¥3,780 million.」
While raw material and logistics costs continued to rise, increased production and exceptional recalculation of prices for unprofitable products eased the unprofitability of the infusion business and improved the cost of sales ratio. Operating profit increased 110.3% year on year and ordinary profit increased 102.4%. - FY2025-H1First-half improvement in infusion-product profitability and the cost ratioAnnual report
「On the earnings front, although raw material and logistics-related costs and other expenses continued to rise, the unprofitability of the infusion business as a whole eased due to increased production and the effects of exceptional recalculation of prices for unprofitable products. As a result, the cost of sales ratio improved slightly, operating profit increased ¥1,335 million (121.4%) to ¥2,434 million from the same period of the previous year, ordinary profit increased ¥1,045 million (95.2%) to ¥2,143 million, and interim net profit increased ¥818 million (114.2%) to ¥1,535 million.」
While raw material and logistics-related costs and other expenses continued to rise, increased production and exceptional recalculation of prices for unprofitable products eased the unprofitability of the infusion business as a whole and slightly improved the cost of sales ratio. Operating profit increased 121.4% year on year. - FY2024Updated for the full-year increase in the cost ratio and decline in profitAnnual report
「The company worked to reduce costs, including by lowering manufacturing costs. For the fiscal year, however, gross profit increased while operating profit and all profit measures below it declined.」
While working to lower manufacturing costs and implement other cost reductions, the cost of sales ratio increased from 73.1% in the previous fiscal year to 75.0%, and operating profit and all profit measures below it declined. - FY2024-Q3Updated for the third-quarter increase in the cost ratio and decline in profit due to soaring raw material pricesAnnual report
「On the earnings front, the higher cost of sales ratio resulting from soaring raw material prices affected results. Operating profit was ¥1,843 million, down ¥122 million (6.3%) from the same quarter of the previous year, ordinary profit was ¥1,829 million, down ¥231 million (11.2%), and quarterly net profit was ¥1,227 million, down ¥266 million (17.8%).」
Against a backdrop of a higher cost of sales ratio due to soaring raw material prices, operating profit, ordinary profit and quarterly net profit declined year on year. - FY2024-Q2Updated for the first-half increase in the cost ratio and decline in profit due to soaring raw material pricesAnnual report
「On the earnings front, the higher cost of sales ratio resulting from soaring raw material prices affected results. Operating profit was ¥1,099 million, down ¥185 million (14.4%) from the same quarter of the previous year, ordinary profit was ¥1,098 million, down ¥301 million (21.5%), and quarterly net profit was ¥717 million, down ¥301 million (29.6%).」
The higher cost of sales ratio resulting from soaring raw material prices led to year-on-year declines in operating profit, ordinary profit and quarterly net profit. - FY2024-Q1First-quarter increase in the cost ratio due to higher raw material pricesAnnual report
「On the earnings front, operating profit was ¥589 million, down ¥32 million (5.2%) from the same quarter of the previous year due mainly to a higher cost of sales ratio resulting from higher raw material prices. Ordinary profit was ¥658 million, down ¥116 million (15.0%), while quarterly net profit was ¥479 million, down ¥79 million (14.2%).」
Operating profit, ordinary profit and quarterly net profit declined year on year due mainly to a higher cost of sales ratio resulting from higher raw material prices. - FY2023Updated for the full-year cost of sales ratio and profitAnnual report
「The company worked to reduce costs, including by lowering manufacturing costs, and focused on promoting sales of generic drugs in addition to its existing core products. As a result, gross profit and all profit measures below it increased.」
While working to lower manufacturing costs and implement other cost reductions, the cost of sales ratio increased from 73.0% in the previous fiscal year to 73.1%, but the operating margin rose from 3.9% to 4.3%, and all profit measures increased. - FY2023-Q2AdvancedAnnual report
「Against this backdrop, in the pharmaceuticals business for the cumulative second quarter, revenue was ¥25,283 million, up ¥404 million (1.6%) from the same quarter of the previous year. In addition, as the cost of sales ratio improved by 0.6 percentage points, gross profit increased ¥259 million (3.8%) to ¥6,998 million and operating profit increased ¥27 million (2.3%) to ¥1,240 million.」
The company stated that the 0.6 percentage-point year-on-year improvement in the pharmaceuticals business cost of sales ratio contributed to higher revenue, gross profit and operating profit. - FY2023-Q1AdvancedAnnual report
「Against this backdrop, in the pharmaceuticals business for the cumulative first quarter, revenue was ¥12,323 million, down ¥232 million (1.9%) from the same quarter of the previous year. However, cost of sales fell ¥281 million (3.1%) to ¥8,827 million, and the cost of sales ratio improved by 0.9 percentage points. As a result, gross profit increased ¥48 million (1.4%) to ¥3,495 million, while operating profit increased ¥6 million (1.0%) to ¥600 million, compared with the same quarter of the previous year.」
The company stated that cost of sales declined 3.1% year on year and the cost of sales ratio improved by 0.9 percentage points, resulting in higher gross profit and operating profit despite lower revenue. - FY2022Updated: full-year increase in the cost-of-sales ratio and profit declineAnnual report
「The company has worked to reduce costs, including by lowering manufacturing costs. However, for the fiscal year, gross profit and all profit measures below it declined. Cost of sales was ¥35,142 million, the cost of sales ratio was 73.0%, operating profit was ¥1,924 million and the operating margin was 3.9%.」
While working to lower manufacturing costs and implement other cost reductions, the full-year cost of sales ratio was 73.0%, and gross profit and all profit measures below it declined. - FY2022-Q3Updated for the third quarter increase in cost of sales and decline in gross profitAnnual report
「Against this backdrop, for the cumulative third quarter, the pharmaceuticals business continued to focus on promoting generic-drug sales, as it had in the previous fiscal year. Revenue increased to ¥3,814.0 million, up ¥5.1 million, or 0.1%, from the same quarter of the previous year. However, gross profit decreased to ¥1,031.9 million, down ¥86.7 million, or 7.8%, as cost of sales increased to ¥2,782.0 million, up ¥91.8 million, or 3.4%, from the same quarter of the previous year.」
In the pharmaceuticals business, cost of sales increased 3.4% year on year and gross profit declined 7.8%. On a company-wide basis, the higher cost of sales ratio resulting from drug price revisions and other factors was also cited as a factor behind the decline in profit. - FY2022-Q2Updated for higher costs due to drug price revisions and other factorsAnnual report
「As a result, for the cumulative second quarter, revenue was ¥24,966 million, up ¥36 million (0.1%) from the same period of the previous year. On the earnings front, operating profit was ¥1,253 million, down ¥451 million (26.5%) from the same period of the previous year, due mainly to an increase in the cost of sales ratio resulting from drug price revisions and other factors. Ordinary profit was ¥1,353 million, down ¥336 million (19.9%), while quarterly net profit was ¥1,043 million, down ¥249 million (19.3%).」
Against a backdrop of a higher cost of sales ratio due to drug price revisions and other factors, operating profit, ordinary profit and quarterly net profit declined year on year. In the pharmaceuticals business, cost of sales increased 3.7% year on year, while gross profit declined 8.3%. - FY2022-Q1Increase in the cost-of-sales ratio due to drug price revisions and other factorsAnnual report
「On the earnings front, operating profit was ¥612 million, down ¥355 million (36.7%) from the same quarter of the previous year, due mainly to an increase in the cost of sales ratio resulting from drug price revisions and other factors. Ordinary profit was ¥780 million, down ¥229 million (22.7%), while quarterly net profit was ¥547 million, down ¥173 million (24.1%).」
Against a backdrop of a higher cost of sales ratio due to drug price revisions and other factors, operating profit, ordinary profit and quarterly net profit declined year on year. - FY2021AdvancedAnnual report
「In the pharmaceuticals business for the fiscal year, focusing on promoting generic-drug sales resulted in revenue growth of ¥234.9 million, or 5.0%, from the previous year. The cost-of-sales ratio declined 1.4%, and gross profit increased by ¥134.3 million, or 10.6%.」
The company states that the cost-of-sales ratio declined 1.4% year on year, increasing gross profit by ¥134.3 million, or 10.6%. - FY2021-Q3AdvancedAnnual report
「The cost-of-sales ratio declined 1.9% from the same quarter of the previous year, while selling, general and administrative expenses declined 1.3%, resulting in higher profit at each level.」
For the cumulative third quarter, the cost-of-sales ratio declined 1.9% year on year and selling, general and administrative expenses also declined 1.3%, resulting in higher profit at each level. - FY2021-Q2AdvancedAnnual report
「The company also worked to reduce manufacturing costs, lowering the cost-of-sales ratio by 2.0% from the same quarter of the previous year. Together with lower selling, general and administrative expenses, this resulted in higher profit at each level.」
The company states that reducing manufacturing costs lowered the cost-of-sales ratio by 2.0% year on year and, together with lower selling, general and administrative expenses, led to higher profit at each level. - FY2021-Q1AdvancedAnnual report
「The company also worked to reduce manufacturing costs, lowering the cost-of-sales ratio by 1.1% from the same quarter of the previous year. Together with lower selling, general and administrative expenses, this resulted in higher profit at each level.」
The company states that reducing manufacturing costs lowered the cost-of-sales ratio by 1.1% year on year and, together with lower selling, general and administrative expenses, led to higher profit at each level. - FY2020Updated: full-year increase in the cost-of-sales ratio and profit declineAnnual report
「The company has worked to reduce costs, including manufacturing costs, but for the fiscal year, the cost-of-sales ratio increased and all profit levels below gross profit declined, mainly due to higher depreciation expenses resulting from the start of operations at new manufacturing facilities and other factors.」
The company pursued lower manufacturing costs and other cost reductions, but states that the full-year cost-of-sales ratio increased and all profit levels declined due to higher depreciation expenses and other factors associated with the start-up of new manufacturing facilities. - FY2020-Q3Third-quarter increase in cost of sales and decline in gross profitAnnual report
「In the pharmaceuticals business for the cumulative third quarter, focusing on promoting sales of the Kindaly dialysis agent for artificial kidneys, generic drugs and other products resulted in revenue growth of ¥61.1 million, or 1.7%, from the same quarter of the previous year. However, gross profit declined by ¥47.6 million, or 4.6%, as cost of sales increased by ¥108.7 million, or 4.3%.」
Higher sales from promotional activities were offset by a ¥108.7 million, or 4.3%, increase in cost of sales, resulting in a ¥47.6 million, or 4.6%, decline in gross profit. - FY2020-Q2First-half increase in the cost-of-sales ratioAnnual report
「In the pharmaceuticals business for the cumulative second quarter, focusing on promoting sales of the Kindaly dialysis agent for artificial kidneys, generic drugs and other products resulted in revenue growth of ¥72.7 million, or 3.2%, from the same quarter of the previous year. However, gross profit declined by ¥21.7 million, or 3.2%, as cost of sales increased by ¥94.5 million, or 5.9%.」
In the first half, revenue increased, while cost of sales rose by ¥94.5 million, or 5.9%, and gross profit declined by ¥21.7 million, or 3.2%. - FY2020-Q1Updated: first-quarter cost-of-sales ratioAnnual report
「In the pharmaceuticals business for the cumulative first quarter, the cost-of-sales ratio increased 0.4% from the same quarter of the previous year. However, as a result of focusing on promoting sales of the Kindaly dialysis agent for artificial kidneys, generic drugs and other products, revenue increased by ¥39.3 million, or 3.5%, and gross profit increased by ¥7.3 million, or 2.2%.」
In the first quarter, the cost-of-sales ratio increased 0.4% year on year, while gross profit increased by ¥7.3 million, or 2.2%, on higher revenue. - FY2019AdvancedAnnual report
「In the pharmaceuticals business for the fiscal year, revenue increased by ¥17.7 million, or 0.4%, from the previous year, despite lower revenue from some products, including Sublood BSG, a hemofiltration replacement fluid for artificial kidneys. This was attributable to contributions from generic drugs. The cost-of-sales ratio declined 0.2% due to lower manufacturing costs and other factors, while gross profit increased by ¥15.0 million, or 1.1%.」
The company states that lower manufacturing costs and other factors reduced the cost-of-sales ratio by 0.2%, increasing gross profit by ¥15.0 million. - FY2019-Q3AdvancedAnnual report
「In the pharmaceuticals business for the cumulative third quarter, revenue increased by ¥16.9 million, or 0.5%, from the same quarter of the previous year. By working to improve productivity for flagship products and others, the company reduced cost of sales by ¥3.9 million, or 0.2%, and the cost-of-sales ratio by 0.5%, resulting in a ¥20.8 million, or 2.1%, increase in gross profit.」
The company states that improved productivity for flagship products and others reduced cost of sales for the cumulative third quarter by ¥3.9 million and the cost-of-sales ratio by 0.5%, increasing gross profit by ¥20.8 million. - FY2019-Q2AdvancedAnnual report
「In the pharmaceuticals business for the cumulative second quarter, revenue declined by ¥11.5 million, or 0.5%, from the same quarter of the previous year. However, by working to improve productivity for flagship products and others, the company reduced cost of sales by ¥23.0 million, or 1.4%, and the cost-of-sales ratio by 0.6%, resulting in a ¥11.4 million, or 1.7%, increase in gross profit.」
The company states that improved productivity for flagship products and others reduced cost of sales for the first half by ¥23.0 million and the cost-of-sales ratio by 0.6%, increasing gross profit by ¥11.4 million. - FY2019-Q1AdvancedAnnual report
「In the pharmaceuticals business for the cumulative first quarter, revenue declined by ¥15.0 million, or 1.3%, from the same quarter of the previous year. However, by working to improve productivity for flagship products and others, the company reduced cost of sales by ¥18.0 million, or 2.2%, and the cost-of-sales ratio by 0.6%, resulting in a ¥2.9 million, or 0.9%, increase in gross profit.」
The company states that improved productivity for flagship products and others reduced cost of sales for the cumulative first quarter by ¥18.0 million and the cost-of-sales ratio by 0.6%, increasing gross profit by ¥2.9 million. - FY2018AdvancedAnnual report
「In the pharmaceuticals business for the fiscal year, revenue declined by ¥88.3 million, or 1.9%, from the previous year. However, by working to improve productivity for flagship products and others, the company reduced cost of sales by ¥91.1 million, or 2.7%, and the cost-of-sales ratio by 0.6%, resulting in a ¥2.7 million, or 0.2%, increase in gross profit.」
The company states that improved productivity for flagship products and others reduced cost of sales by ¥91.1 million and the cost-of-sales ratio by 0.6%, increasing gross profit by ¥2.7 million. - FY2018-Q3RestatedAnnual report
「The company will promote capital investment focused on production efficiency and rationalization aimed at lowering manufacturing costs in response to drug price reductions resulting from recent measures to contain national healthcare spending. It will manufacture pharmaceuticals such as Sublood BSG, a hemofiltration replacement fluid for artificial kidneys, using safer containers suited to the needs of medical institutions. In cooperation with the Corporate Reliability Assurance Division, it will thoroughly implement quality control and devote all available resources to improving the reliability of its product brands. It will also actively invest in developing systems, including cooperation with the R&D Center, in preparation for the development and mass production of new products.」
The company continues to pursue production efficiency, manufacturing cost reduction, safer containers, quality control and systems development in preparation for the mass production of new products. - FY2018-Q1RestatedAnnual report
「The company will promote capital investment focused on production efficiency and rationalization aimed at lowering manufacturing costs in response to drug price reductions resulting from recent measures to contain national healthcare spending. It will manufacture pharmaceuticals such as Sublood BSG, a hemofiltration replacement fluid for artificial kidneys, using safer containers suited to the needs of medical institutions. In cooperation with the Corporate Reliability Assurance Division, it will thoroughly implement quality control and devote all available resources to improving the reliability of its product brands. It will also actively invest in developing systems, including cooperation with the R&D Center, in preparation for the development and mass production of new products.」
The company continues to pursue production efficiency, manufacturing cost reduction, safer containers, quality control and systems development in preparation for the mass production of new products. - FY2017RestatedAnnual report
「In production, the company will promote more efficient capital investment and rationalization aimed at lowering manufacturing costs, while thoroughly implementing quality control to improve reliability.」
The company continues to improve reliability through more efficient capital investment, manufacturing cost reduction and quality control. - FY2017-Q3RestatedAnnual report
「The company will promote capital investment focused on production efficiency and rationalization aimed at lowering manufacturing costs in response to drug price reductions resulting from recent measures to contain national healthcare spending. It will manufacture pharmaceuticals such as Sublood BSG, a hemofiltration replacement fluid for artificial kidneys, using safer containers suited to the needs of medical institutions. In cooperation with the Corporate Reliability Assurance Division, it will thoroughly implement quality control and devote all available resources to improving the reliability of its product brands. It will also actively invest in developing systems, including cooperation with the R&D Center, in preparation for the development and mass production of new products.」
The company continues to invest in production efficiency, manufacturing cost reduction, safer containers, quality control and systems development in preparation for the mass production of new products. - FY2017-Q2RestatedAnnual report
「To address drug price reductions resulting from recent measures to contain national healthcare spending, the company will promote capital investment focused on production efficiency and rationalization aimed at lowering manufacturing costs. It will manufacture pharmaceuticals such as Sublood BSG, a hemofiltration replacement fluid for artificial kidneys, using safer containers suited to the needs of medical institutions. In cooperation with the Corporate Reliability Assurance Division, it will thoroughly implement quality control and devote all available resources to improving the reliability of its product brands.」
The company continues manufacturing initiatives including production efficiency, manufacturing cost reduction, safer containers and quality control. - FY2017-Q1RestatedAnnual report
「To address drug price reductions resulting from recent measures to contain national healthcare spending, the company will promote capital investment focused on production efficiency and rationalization aimed at lowering manufacturing costs.」
The company states its policy of continuing to pursue production efficiency, reduce manufacturing costs and invest in capital equipment in response to drug price reductions. - FY2016First statedAnnual report
「The company will promote rationalization focused on more efficient capital investment and lower manufacturing costs, while thoroughly implementing quality control to improve reliability.」
In response to drug price reductions, the company presents production efficiency, cost reduction and quality control as integrated manufacturing initiatives.